

Supplementary Information for

Luminescent pentafluorophenyl-cycloplatinated complexes: synthesis, characterization, photophysics, cytotoxicity and cellular imaging

J. R. Berenguer,^a J. G. Pichel,^{*b} N. Giménez,^a E. Lalinde,^a M. T. Moreno,^{*a} S. Piñeiro-Hermida.^b

^a *Departamento de Química-Centro de Síntesis Química de La Rioja, (CISQ), Universidad de La Rioja, 26006, Logroño, Spain.*

^b *Centro de Investigación Biomédica de La Rioja (CIBIR), Fundación Rioja Salud, 26006, Logroño, Spain.*

Table of contents

Fig. S1 ¹ H NMR spectra of Hbt, 1b , 2b and 3b in CDCl ₃ at 298 K.....	S3
Fig. S2 ¹ H NMR spectra of 1c CDCl ₃ at 298 K and at 223 K	S4
Fig. S3 Variable temperature ¹⁹ F NMR spectra of 1a in CDCl ₃	S5
Fig. S4 Crystal packing of 1a	S6
Fig. S5 View of the secondary interactions in the structure 1c .0.75CH ₂ Cl ₂	S7
Fig. S6 Crystal packing of the complex 2b	S8
Fig. S7 Crystal packing of 3a	S9
Fig. S8 Crystal packing of 3b	S9
Fig. S9 Absorption spectra in CH ₂ Cl ₂ (5 x 10 ⁻⁵ M) at 298 K of a) (1b , 2b and 3b) and the Hbt ligand, b) (1c and 2c) and the Hpq ligand.....	S10
Fig. S10 Excitation and emission spectra of 1a , 1b and 1c in a) CH ₂ Cl ₂ 5 x 10 ⁻⁵ M at 298 K...	S11
Fig. S11 Excitation and emission spectra of 1a , 1b and 1c in solid state a) 298 k, b) at 77 K....	S11
Fig. S12 Normalized excitation and emission spectra of different samples of 1a and 1c in solid state at 298 K: bulk material, ground solid) and crystals obtained from CH ₂ Cl ₂ / <i>n</i> -hexane.....	S12
Fig. S13 Excitation and emission spectra of 2a , 2b and 2c a) in solid state at 298 K, b) in solid state at 77 K.....	S13
Fig. S14 Excitation and emission spectra of 2a , 2b and 2c in CH ₂ Cl ₂ 5 x 10 ⁻⁵ M at 77 K.....	S14
Fig. S15 Normalized excitation and emission spectra of 3a and 3b a) in solid state at 77 K, b)	

CH ₂ Cl ₂ 5x10 ⁻⁵ M at 77 K.....	S14-S15
Table S1. DFT optimized geometries for ground state and triplet state of complexes 1a , 1c 2b and 3a	S16-S17
Fig. S16 Optimized structures of S ₀ and T ₁ states of 1a , 1c 2b and 3a	S17-S18
Table S2 Composition (%) of Frontier MOs in the ground state for complexes 1a , 1c , 2b and 3a in gas phase.....	S19
Fig. S17 Selected frontier Molecular Orbitals for complex 1a	S20
Fig. S18 Selected frontier Molecular Orbitals for complex 1c	S21
Fig. S19 Selected frontier Molecular Orbitals for complex 2b	S22
Fig. S20 Selected frontier Molecular Orbitals for complex 3a	S23
Table S3. Selected vertical excitation energies singlets (S ₀) computed by TD-DFT/ SCRF (CH ₂ Cl ₂) with the orbitals involved for complexes for 1a , 1c , 2b and 3a	S24-S25
Table S4. Composition (%) of frontier molecular orbitals in the first triple-state for 1a , c , 2b and 3a in gas phase	S26
Fig. S21 UV-vis absorption spectra of a) 3a , b) 3b and c) 4 , (5 x 10 ⁻⁵ M) recorded in DMSO (<1%)-cellular medium	S27
Fig. S22 Curves for determination of the IC ₅₀ cytotoxicity values of 3a , 3b and 4	S28
Fig. S23 Fluorescence images of mouse lung embryonic fibroblasts (LMEFs) treated with 3a , and A549 and NL20 cells treated with complex 4	S29
Fig. S24 Comparative normalized excitation and emission spectra of 3a in CH ₂ Cl ₂ and DMSO (5 x 10 ⁻⁵ M) at 298 K.....	S30
Table S5. X-ray Crystallographic Data for 1a , 1c .0.75CH ₂ Cl ₂ , 2b , 3a and 3b	S31
Complete reference 39.....	S31




Fig. S1 Selected region of the ^1H NMR spectra of Hbt, **1b**, **2b** and **3b** in CDCl_3 at 298 K




Fig. S2 ¹H NMR spectra of **1c** CDCl₃ at 298 K and at 223 K




Fig. S3 Variable temperature ^{19}F NMR spectra of **1a** in CDCl_3




Fig. S4 Crystal packing of **1a** showing the intermolecular contacts. The supramolecular packing is formed by chains supported by intermolecular $\pi \cdots \pi$ (pink lines) involving Hthpy and C_6F_5 ligands with interplanar distances of 3.36 Å. These $\pi \cdots \pi$ interactions are supported by $F_{C_6F_5} \cdots H_{Hthpy}$ (2.38 Å) and $H_{Hthpy} \cdots S_{Hthpy}$ (2.86 Å) secondary interactions (blue lines).




Fig. S5 View of the secondary interactions in the structure **1c**. $0.75\text{CH}_2\text{Cl}_2$. $\text{F}_{\text{C6F5}} \cdots \text{C}_{\text{C6F5}}$ (3.04 Å), $\text{F}_{\text{C6F5}} \cdots \text{C}_{\text{Hpq}}$ (3.15 Å) and $\text{F}_{\text{C6F5}} \cdots \text{H}_{\text{Hpq}}$ (2.59 Å) interactions are observed.




Fig. S6 Crystal packing of the complex **2b** showing a) The supramolecular packing of the dimers supported by intermolecular $\pi \cdots \pi$ interactions (pink lines) involving Hbt ligands with interplanar distances of 3.31 Å ($C_{Hbt} \cdots C_{Hbt}$) and 3.50 Å ($S_{Hbt} \cdots C_{Hbt}$) supported by $C_{C6F5} \cdots S_{bt}$ (3.48 Å) secondary interactions (blue). b) The disposition of the chains showing the interactions between dimers supported by $\pi \cdots \pi$ interactions ($C_{bt} \cdots C_{bt}$, 3.35, pink lines) and weak interactions (blue) [$H_{bt} \cdots F_{C6F5}$ (2.66 Å), $H_{bt} \cdots C_{bt}$ (2.81 Å), $C_{bt} \cdots F_{C6F5}$ (3.12 Å)]




Fig. S7 Crystal packing of **3a** showing the intermolecular contacts. The supramolecular packing is formed by chains supported by intermolecular $\pi \cdots \pi$ (pink lines) involving two thpy ligands (3.33-3.40 Å). These $\pi \cdots \pi$ interactions are supported by $F_{C6F5} \cdots H_{thpy}$ (2.60 Å) (blue lines).






Fig. S8 View of the secondary interactions present in the structure **3b** showing the interactions $F_{C6F5} \cdots F_{C6F5}$ (2.84 Å), $F_{C6F5} \cdots H_{bt}$ (2.55-2.64 Å) and $F_{C6F5} \cdots S_{bt}$ (3.15-3.25 Å).



a)



b)

Fig. S9. Absorption spectra in CH_2Cl_2 (5×10^{-5} M) at 298 K of a) the bt series of complexes (**1b**, **2b** and **3b**) and the Hbt ligand, b) the pq series of complexes (**1c** and **2c**) and the Hpq ligand




Fig. S10. Normalized excitation and emission spectra of **1a**, **1b** and **1c** in CH_2Cl_2 5×10^{-5} M at 298 K




Fig. S11 Normalized excitation and emission spectra of **1a**, **1b** and **1c** in solid state at 77 K.




Fig. S12a Normalized excitation and emission spectra of different samples of **1a** in solid state at 298K: bulk material (black; the shape depends on the excitation wavelength), ground solid (red) and crystals obtained from $\text{CH}_2\text{Cl}_2/n$ -hexane (blue) (λ_{exc} 365 nm)




Fig. S12b Normalized excitation and emission spectra of different samples of **1c** in solid state at 298K: bulk material or ground solid (red) and crystals obtained from $\text{CH}_2\text{Cl}_2/n$ -hexane (blue) (λ_{exc} 365 nm)




Fig. S13a Normalized excitation and emission spectra of **2a**, **2b** and **2c** in solid state at 298 K

Fig. S13b Normalized excitation and emission spectra of **2a**, **2b** and **2c** in solid state at 77 K.





Fig. S14
excitation
spectra of
in CH_2Cl_2
77 K.



Normalized
and emission
2a, **2b** and **2c**
 5×10^{-5} M at





Fig. S15a Normalized excitation and emission spectra of **3a** and **3b** in solid state at 77 K



b)

Fig. S15b Normalized excitation and emission spectra of **3a** and **3b** in CH_2Cl_2 $5 \times 10^{-5} \text{ M}$ at 77 K.

Table S1. DFT optimized geometries for ground state and triplet state of complexes **1a**, **1c** **2b** and **3a**


1a			
	X-Ray	S ₀	T ₁
Pt-N(1)	2.110(3)	2.214	2.220
Pt-N(2)	2.111(3)	2.217	2.195
Pt-C(19)	2.012(4)	2.021	2.023
Pt-C(25)	2.015(4)	2.021	2.029
C(14)-C(15)	1.464(6)	1.469	1.393
Pt-H(16)	3.044	2.895	2.675
N(1)-Pt-N(2)	88.97(12)	89.65	88.62
C(19)-Pt-N(2)	88.80(14)	91.01	92.41
C(25)-Pt-N(1)	89.79(14)	91.88	91.77
C(19)-Pt-C(25)	92.46(16)	87.45	97.20

1c			
	X-Ray	S ₀	T ₁
Pt-N(1)	2.173(6)	2.251	2.163
Pt-N(2)	2.133(5)	2.251	2.254
Pt-C(31)	2.012(8)	2.030	2.047
Pt-C(37)	2.011(6)	2.030	2.023
Pt-H(14)	2.773	2.677	2.665
Pt-H(29)	2.759	2.677	2.710
N(2)-Pt-N(1)	90.1(2)	92.7	92.5
C(31)-Pt-N(2)	91.5(2)	90.9	90.0
C(31)-Pt-C(37)	87.2(3)	85.5	85.9
C(37)-Pt-N(1)	91.4(2)	90.9	91.5

2b			
	X-Ray	S ₀	T ₁
Pt-N(1)	2.101(3)	2.194	2.130
Pt-N(2)	2.152(3)	2.244	2.263
Pt-C(9)	2.007(3)	2.004	1.981
Pt-C(27)	2.005(4)	2.019	2.034
Pt-H(22)	2.587	2.831	2.890
Pt-H(15)	2.786	2.881	2.908

N(1)-Pt-N(2)	96.90(12)	99.14	98.61
C(27)-Pt-N(2)	90.65(12)	87.20	86.00
C(27)-Pt-C(9)	91.20(15)	93.72	93.36
C(9)-Pt-N(1)	81.37(15)	79.95	82.034

3a			
	X-Ray	S ₀	T ₁
Pt-N(1)	2.009(7)	2.168	2.139
Pt-C(1)	2.049(9)	2.005	1.975
Pt-S(2)	2.296(2)	2.438	2.450
Pt-C(10)	2.007(10)	2.034	2.041
O(1)-S(2)	1.472(6)	1.510	1.510
S(2)-C(16)	1.789(9)	1.819	1.820
S(2)-C(17)	1.795(9)	1.820	1.821
C(10)-Pt(1)-C(1)	91.5(4)	91.9	91.4
C(1)-Pt(1)-N(1)	79.0(3)	79.8	81.1
C(10)-Pt(1)-S(2)	92.0(3)	90.6	90.2
N(1)-Pt-S(2)	98.09(18)	97.8	97.4
O(1)-S(2)-Pt(1)	116.9(3)	120.1	120.4






Fig. S16 Optimized structures of S_0 and T_1 states of **1a**, **1c**, **2b** and **3a**

Table S2 Composition (%) of Frontier MOs in the ground state for complexes **1a**, **1c**, **2b** and **3a** in gas phase.

1a							1c					
MO	eV	C ₆ F ₅ (1)	C ₆ F ₅ (2)	Pt	Hthpy (1)	Hthpy (2)	eV	C ₆ F ₅ (1)	C ₆ F ₅ (2)	Pt	Hpq(1)	Hpq (2)
LUMO+5	-0.15	1	1	2	75	22	-0.3	2	2	2	49	45
LUMO+4	-0.52	24	25	34	10	8	-0.53	25	25	31	10	10
LUMO+3	-1.03	2	1	2	65	30	-0.81	1	1	1	49	48
LUMO+2	-1.18	0	1	1	31	67	-0.89	0	0	1	49	50
LUMO+1	-1.66	0	0	2	72	26	-1.92	0	0	1	49	49
LUMO	-1.74	0	0	1	27	72	-2.02	0	0	1	49	49
HOMO	-5.82	3	3	73	10	11	-5.86	4	4	82	5	5
HOMO-1	-6.02	34	31	32	2	1	-6.01	28	28	30	7	7
HOMO-2	-6.23	17	19	33	14	17	-6.15	26	26	30	9	9
HOMO-3	-6.39	18	1	16	45	21	-6.37	46	49	3	1	1
HOMO-4	-6.39	41	45	3	4	7	-6.38	6	4	39	26	26
HOMO-5	-6.46	41	52	1	5	1	-6.48	48	47	4	1	1
2b							3a					
	eV	bt	Hbt	C ₆ F ₅	Pt		eV	C ₆ F ₅	thpy	dmsO	Pt	
LUMO+5	-0.3	21	45	16	13	0.1	31	11	27	30		
LUMO+4	-0.43	37	57	2	4	0.03	82	5	1	11		
LUMO+3	-0.52	51	47	0	2	0.01	65	7	15	13		
LUMO+2	-0.61	15	77	2	5	-0.6	33	24	11	32		
LUMO+1	-1.91	4	94	0	1	-1.05	0	98	0	1		
LUMO	-1.94	91	5	0	4	-1.84	1	89	2	8		
HOMO	-5.82	63	1	0	35	-5.74	0	85	1	14		
HOMO-1	-5.97	4	5	4	87	-6.33	68	5	3	25		
HOMO-2	-6.12	3	3	66	28	-6.41	15	4	0	81		
HOMO-3	-6.32	58	1	3	38	-6.46	50	42	0	7		
HOMO-4	-6.39	1	1	99	0	-6.51	49	41	0	10		
HOMO-5	-6.53	69	9	2	20	-6.92	4	14	0	81		




Fig. S17 Selected frontier Molecular Orbitals for complex **1a**.




Fig. S18 Selected frontier Molecular Orbitals for complex 1c.




Fig. S19 Selected frontier Molecular Orbitals for complex **2b**.




Fig. S20 Selected frontier Molecular Orbitals for complex 3a.

Table S3 Selected vertical excitation energies singlets (S_0) and first triplets computed by TD-DFT/ SCRf (CH_2Cl_2) with the orbitals involved for complexes for **1a**, **1c**, **2b** and **3a**.


	State	$\lambda_{\text{ex}}(\text{calc})(\text{nm})$	f^{a}	Transition (% Contribution)
1a	T ₁	435,93	0,0	H-6->LUMO (11%), H-2->LUMO (10%), HOMO->LUMO (27%)
	T ₂	416,32	0,0	H-3->L+1 (21%), HOMO->L+1 (13%)
	S ₁	374,76	0,0125	HOMO->LUMO (98%)
	S ₂	367,86	0,0005	HOMO->L+1 (98%)
	S ₃	339,32	0,0043	H-1->LUMO (97%)
	S ₄	332,56	0,0105	H-1->L+1 (96%)
	S ₅	322,96	0,0102	H-2->LUMO (92%)
	S ₆	318,87	0,0256	H-2->L+1 (74%), HOMO->L+2 (13%)
	S ₇	316,95	0,0081	H-2->L+1 (15%), HOMO->L+2 (79%)
	S ₈	313,46	0,0021	HOMO->L+3 (42%), HOMO->L+4 (41%)
	S ₉	308,42	0,1169	H-4->LUMO (11%), H-3->LUMO (74%)
	S ₁₀	303,59	0,0496	H-4->L+1 (10%), H-3->L+1 (77%)
S ₁₁	300,08	0,0114	HOMO->L+3 (49%), HOMO->L+4 (38%)	
1c	T ₁	462,69	0,0	H-6->L+1 (18%), H-4->LUMO (28%), H-2->L+1 (11%), H-1->LUMO (18%)
	T ₂	461,09	0,0	H-6->LUMO (20%), H-4->L+1 (25%), H-2->LUMO (16%), H-1->L+1 (16%)
	T ₃	405,36	0,0	HOMO->LUMO (94%)
	S ₁	400,50	0,0075	HOMO->LUMO (98%)
	S ₂	388,44	0,0006	HOMO->L+1 (99%)
	S ₃	365,57	0,0164	H-1->LUMO (95%)
	S ₄	354,44	0,0414	H-2->LUMO (21%), H-1->L+1 (74%)
	S ₅	350,28	0,0035	H-2->LUMO (74%), H-1->L+1 (21%)
	S ₆	342,58	0,003	H-2->L+1 (93%)
	S ₇	333,91	0,0563	H-4->LUMO (89%)
	S ₈	322,70	0,0096	H-4->L+1 (16%), H-3->LUMO (76%)
	S ₉	321,28	0,0413	H-4->L+1 (73%), H-3->LUMO (13%)
	S ₁₀	318,04	0,0044	H-5->LUMO (47%), H-3->L+1 (50%)
	S ₁₁	311,25	0,0152	HOMO->L+4 (85%)
S ₁₂	308,11	0,0058	H-7->LUMO (17%), H-6->LUMO (72%)	
S ₁₃	306,96	0,0046	H-5->LUMO (46%), H-3->L+1 (45%)	
2b	T ₁	491,98	0,0	H-3->LUMO (11%), HOMO->LUMO (76%)
	T ₂	419,99	0,0	H-6->L+1 (50%), H-1->L+1 (14%)
	S ₁	394,56	0,099	HOMO->LUMO (84%)
	S ₂	389,66	0,0208	H-1->LUMO (87%)
	S ₃	379,23	0,0077	H-1->L+1 (48%), HOMO->L+1 (45%)
	S ₄	374,07	0,0031	H-1->L+1 (46%), HOMO->L+1 (50%)
	S ₅	351,52	0,0061	H-2->LUMO (93%)
	S ₆	347,42	0,0161	H-2->L+1 (94%)
	S ₇	330,68	0,1064	H-3->LUMO (78%)
S ₈	327,82	0,0124	H-3->L+1 (83%)	

	S ₉	316,70	0,002	H-4->L+1 (91%)
	S ₁₀	312,08	0,0185	H-4->LUMO (86%)
	S ₁₁	309,79	0,317	H-5->LUMO (76%)
	S ₁₂	302,74	0,0264	H-5->L+1 (85%)
3a	T ₁	527,81	0,0	HOMO->LUMO (90%)
	T ₂	361,53	0,0	H-3->LUMO (17%), HOMO->L+1 (60%)
	S ₁	374,06	0,1164	HOMO->LUMO (94%)
	S ₂	337,60	0,0081	H-2->LUMO (11%), H-1->LUMO (89%)
	S ₃	314,37	0,0052	H-2->LUMO (84%), H-1->LUMO (10%)
	S ₄	304,447	0,0503	H-5->LUMO (21%), H-3->LUMO (21%), HOMO->L+1 (51%)
	S ₅	298,407	0,1355	H-5->LUMO (14%), H-3->LUMO (69%), HOMO->L+1 (11%)
	S ₆	295,56	0,0014	HOMO->L+2 (89%)
	S ₇	290,13	0,0043	H-4->LUMO (94%)
	S ₈	285,92	0,1805	H-5->LUMO (38%), H-1->L+2 (20%), HOMO->L+1 (27%)
S ₉	282,45	0,1241	H-5->LUMO (22%), H-2->L+2 (11%), H-1->L+2 (55%)	


a) Oscillator Strength

Table S4 Composition (%) of frontier molecular orbitals in the first triple-state for **1a**, **1c**, **2b** and **3a** in CH₂Cl₂


1a						
	eV	C ₆ F ₅ (1)	C ₆ F ₅ (2)	Hthpy(1)	Hthpy(2)	Pt
SOMO	-3.83	0	0	1	98	1
SOMO-1	-5.99	4	5	14	4	74
1c						
	eV	C ₆ F ₅ (1)	C ₆ F ₅ (2)	Hpq(1)	Hpq(2)	Pt
SOMO	-3.84	0	0	0	98	1
SOMO-1	-6.02	8	5	5	7	74
2b						
	eV	C ₆ F ₅	Hbt	bt	Pt	
SOMO	-3.64	0	0	95	5	
SOMO-1	-6.07	1	1	75	23	
3a						
	eV	C ₆ F ₅	thpy	dmso	Pt	
SOMO	-3.61	0	92	1	6	
SOMO-1	-6.24	0	78	1	20	



a)



b)



c)

Fig. S21 UV-vis absorption spectra of a) **3a**, b) **3b** and c) **4**, (5×10^{-5} M) recorded in DMSO (<1%)-cellular medium (see text) after been kept at room temperature since 0 h to 96 h (intervals in legends)




Fig. S22 Dose-response curves for determination of the IC_{50} cytotoxicity values of **3a**, **3b** and **4**, and their comparison with cisplatin, in A549 and NL20 cell lines. The IC_{50} values correspond to the dose required to inhibit 50% cellular growth, determined from the dose-dependence of surviving cells after cellular exposure to compounds for 72 h.




Fig. S23 Fluorescence images of mouse lung embryonic fibroblasts (LMEFs) treated with **3a**, and A549 and NL20 cells treated with complex **4**. Living LMEFs were treated with complex **3a** (A-E), and A549 and NL20 cells were treated with complex **4** (F-O) (both 40 μ M), in combination with the DNA binder Hoechst 33258 (3.2 μ M) for 30 min. Cells were visualized by microscopy either for Nomarski white-light transmission (A, E and K), or for fluorescence emission in green (B, G and L), red (C, H and M) and blue (D, I and N). Overlay of Nomarski, green, red and blue images are shown in right panels (E, J and O) (merged). Note that in LMEFs **3a** stains the cytoplasm, stronger in perinuclear areas (white arrows), nuclei (white arrowheads) and nucleoli (yellow arrows) in green, and in red with less intensity. Complex **4** stains the cytoplasm of A549 cells, stronger in the perinuclear structures (white arrows), and most nuclei (white arrowheads) including nucleoli, both in green, and in red (with less intensity). In NL20 cells, complex **4** stains the perinuclear cytoplasm (white arrows) and nucleoli (yellow arrows) in green, and in red with less intensity. Scales bar in E and O: 30 μ m.




Fig. S24 Comparative normalized excitation and emission spectra of **3a** in CH_2Cl_2 and DMSO (5×10^{-5} M) at 298 K

Table S5 X-ray Crystallographic Data for 1a, 1c.0.75CH₂Cl₂, 2b, 3a and 3b

	1a	1c.0.75CH₂Cl₂	2b	3a	3b
Empirical formula	C30 H14 F10 N2 Pt S2	C42 H22 F10 N2 Pt	C32 H17 F5 N2 Pt S2	C17 H12 F5 N O Pt S2	C21 H14 F5 N O Pt S2
F_w	851.64	939.70	783.68	600.49	650.54
T (K)	120(1)	173(1)	173(1)	173(1)	173 (1)
crystal system, space group	Orthorhombic, P bca	Monoclinic, P 21/n	Monoclinic, P 21/a	Triclinic, P -1	Triclinic, P -1
a(Å)	12.6350(2)	8.2453(2)	14.9033(5)	6.7971(2)	7.5475(2)
b(Å)	18.4730(3)	26.5307(7)	12.3384(4)	10.3253(5)	11.4335(5)
c(Å)	23.9410(3)	16.6300(4)	15.0986(4)	12.4185(6)	11.8516(5)
α (deg)	90	90	90.	84.911(2)	99.861(2)
β (deg)	90	94.703(2)	105.414(2)	85.894(3)	98.362(2)
γ (deg)	90	90	90.	88.980(3)	91.328(3)
volume (Å ³)	5587.98(14)	3625.62(16)	1129.94(9)	865.84(6)	995.69(7)
Z	8	4	4	2	2
D_{calcd} (Mg/m ³)	2.025 Mg/m ³	1.722	1.945	2.303	2.170
absorption coefficient (mm ⁻¹)	5.264	3.955	5.461	8.403	7.316
F(000)	3264	1824	1512	568	620
θ range for data collection (deg)	3.37 to 25.68	1.449 to 25.026	3.258 to 27.476	1.650 to 24.711	3.470 to 24.707
no of data / restraints / params	5299 / 0 / 358	6376 / 0 / 496	6068 / 0 / 379	2795 / 0 / 215	3284 / 0 / 280
goodness-of-fit on F^2 ^[a]	1.037	1.128	1.096	1.197	0.938
final R indices [$>2\sigma(I)$] ^[a]	R1 = 0.0260, wR2 = 0.0543	R1 = 0.0445, wR2 = 0.1169	R1 = 0.0262, wR2 = 0.0551	R1 = 0.0547, wR2 = 0.1467	R1 = 0.0345, wR2 = 0.0932
R indices (all data) ^[a]	R1 = 0.0340, wR2 = 0.0583	R1 = 0.0551, wR2 = 0.1250	R1 = 0.0317, wR2 = 0.0571	R1 = 0.0556, wR2 = 0.1501	R1 = 0.0349, wR2 = 0.0939
largest diff peak and hole (e.Å ⁻³)	2.328 and -1.255	2.131 and -2.136	1.417 and -0.779	2.834 and - 3.185	1.768 and - 2.827

^[a] $R1 = \Sigma(|F_o| - |F_c|) / \Sigma|F_o|$; $wR2 = [\Sigma w(F_o^2 - F_c^2)^2 / \Sigma w F_o^2]^{1/2}$; goodness of fit = $\{\Sigma[w(F_o^2 - F_c^2)^2] / (N_{\text{obs}} - N_{\text{param}})\}^{1/2}$; $w = [\sigma^2(F_o) + (g_1 P)^2 + g_2 P]^{-1}$; $P = [\max(F_o^2; 0 + 2F_c^2)]/3$.

Complete reference 39:

Gaussian 09, Revision B.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2010.